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Background 
Every year, 14.8 million adults (6.7% of the US population) suffer from ma-
jor depressive disorder.1  According to the Diagnostic and Statistical Manual of 
Mental Disorders, depression is identified by changes in weight, energy, sleep, 
and concentration, feelings of worthlessness and guilt, and suicide ideation per-
sisting two weeks or longer.2  At least one of the symptoms must be either de-
pressed mood or loss of pleasure.2   
In terms of treatment, pharmacotherapy for depression achieves mixed re-
sults, and patient success in achieving remission often dependends on several 
factors.  In double-blind, randomized controlled trials, antidepressants demon-
strate small yet statistically significant advantages over placebo3 but do not sub-
stantially improve patient symptoms.  Meta-analyses have shown that almost 
38% of patients on antidepressants did not achieve a response to treatment and 
54% did not achieve remission.4  While current antidepressant therapy options 
may help patients relieve some symptoms of depression, studies have found vari-
able efficacy results overall. 
The monoamine hypothesis provided the most well understood framework 
for treating depression.5  It proposed that decreased function of norepinephrine 
and/or serotonin caused depression and reversal of the neurochemical imbalance 
restored health.5  Unfortunately, depression affects the brain in a much more 
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complicated and deceptive manner.  Stress and depression are associated with 
increased serotonin activity in the amygdala and prefrontal cortex (PFC) but de-
creased activity in the hippocampus.5  Selective serotonin reuptake inhibitors 
(SSRIs) increase serotonin levels throughout the entire brain, making SSRIs bene-
ficial in the hippocampus but counterproductive in the amygdala and PFC.5  Sero-
tonin in the amygdala actually has a pro-anxiety effect, which counteracts the 
antidepressant action in the hippocampus.5  Numerous neurobiological factors 
need to be considered when treating depression. 
Several symptoms constitute a depression diagnosis, and patient presenta-
tion can be variable.5  Diagnosis of depression requires presence of five out of 
nine symptoms, so it is theoretically possible for two clinically depressed patients 
to only share one symptom.6  Individual symptoms are linked to specific biologi-
cal components and pathways, so it seems unlikely, for example, that the neural 
circuit mediating anhedonia would also be involved in feelings of guilt.7  Distin-
guishing the neurobiological mechanism for each symptom of a patient’s depres-
sion and accurately prescribing the right medication to address these symptoms 
is not clinically feasible, at least with the current medical understanding.  But im-
proving our understanding of how to treat specific symptoms may be the key to 
improving antidepressant efficacy. 
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Previous studies have not substantially investigated the relationship be-
tween depression and the symptom of anhedonia.  Anhedonia is defined as the 
reduced ability to feel pleasure8, and reports estimate that 37% of depressed in-
dividuals experience clinically significant anhedonia.6  It plays an important role in 
achieving complete recovery from depression because the capacity to feel pleas-
ure is needed for normal decision-making and reward-processing.7  Besides be-
ing one of two core symptoms, anhedonia has been suggested to be an 
endophenotype for depression.  Endophenotypes are subclinical traits associated 
with expression of an illness and represent the genetic liability of the disorder in 
non-affected individuals8, meaning anhedonia may be involved in the hereditabil-
ity of depression.  Many twin and family concordance studies also revealed that 
hedonic capacity may be a heritable trait.9  Another study showed that patients 
who were most anhedonic when depressed continued to have anhedonic re-
sponses after recovering from depression10, implying anhedonia could play a role 
in relapse for patients in remission.8 
The efficacy of current antidepressant therapies in relieving anhedonia is 
uncertain.  Evidence suggests that the most common first-line pharmacothera-
pies, such as SSRIs, do not adequately address motivational and reward-
processing deficits associated with anhedonia.6  The inability to feel pleasure has 
primarily been associated with decreased activity in the mesolimbic dopamine 
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projection from the ventral tegmental area (VTA) of the midbrain to the nucleus 
accumbens.5  The nucleus accumbens and ventral pallidum, both within the basal 
ganglia, have mu opioid and endocannabinoid receptors that mediate hedonic 
perception of rewards; anhedonic individuals with depression have decreased ac-
tivity within these regions.7  Overall, studies have been inconclusive in determin-
ing whether antidepressants positively affect these regions or not.  It is important 
to note that anhedonia is not exclusively a symptom of depression; it is also in-
volved in schizophrenia, Parkinson’s disease, Alzheimer’s disease, substance 
abuse disorder, and eating disorders.7  It may not be reasonable to assume that 
antidepressants can restore the specific neurochemical abnormalities involved in 
anhedonia. 
In a study by Schrader, anhedonia did not correlate with depression severi-
ty in a chronically depressed population.  Over a one-year period, depression se-
verity was significantly reduced in patients who were being treated, while 
anhedonia scores remained relatively unchanged.10  Additionally, self-report as-
sessments of anhedonia are only moderately associated with depression severi-
ty.7  If depression and anhedonia are diverging variables, it brings into question 
the existing strategies used to treat anhedonic depression.  In order to create 
more effective treatments for depressed patients in the future, it will be crucial to 
understand how antidepressant therapies impact anhedonia.  The primary objec-
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tive of this study is to gain insight into whether antidepressants are efficacious in 
relieving anhedonia in patients with Major Depressive Disorder by measuring the 
relationship between anhedonia and depression severity. 
 
Methods 
Participants 
We conducted a cross-sectional survey of adult patients, aged 20 years 
and older, with major depressive disorder and receiving antidepressant treat-
ment.  Patients were included primarily if they had depression.  We also included 
patients receiving multiple antidepressants and patients with the following 
comorbid anxiety disorders:  general anxiety disorder (GAD), post-traumatic 
stress disorder (PTSD), obsessive compulsive disorder (OCD), attention-
deficit/hyperactivity disorder (ADHD), and social anxiety disorder (SAD).  Patients 
with schizophrenia, bipolar disorder, and substance abuse disorder were exclud-
ed.  A 37-question paper survey was distributed to all patients prior to their visit 
with one of the six participating psychiatrists at three outpatient locations (see 
Appendix for entire survey).    
This study was approved by the institutional review boards at Community 
Health Network and Butler University, and patients had the option to opt out of 
the study after reading an informed consent statement. 
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Materials 
The paper survey took approximately 5-7 minutes to complete.  It included 
the Snaith-Hamilton Pleasure Scale (SHAPS) to measure anhedonia (questions 1-
14) and the Clinically Useful Depression Outcome Scale (CUDOS) to assess cur-
rent depression severity (questions 15-32).  Additional questions were included to 
gather demographic data such as age and sex, diagnosed mental illnesses, and 
therapy data.  Relevant therapy data included how long the patient had been tak-
ing antidepressants, the name of prescribed medication(s), and whether the pa-
tient was involved in psychotherapy. 
 
Procedure 
Receptionists for the psychiatrists provided surveys to all patients in the 
waiting room before their visit.  After completion, patients brought the survey to 
the psychiatrist who stored the survey until a researcher could pick it up.  If any 
patient responses indicated thoughts relating to suicide ideation, the psychiatrist 
would address the concerns. 
To score the SHAPS, a response of agree or strongly agree received a 
score of zero, and a response of disagree or strongly disagree received a score of 
one; when the responses were summed, scores greater than two signified pres-
ence of anhedonia.11  The CUDOS had a range of scores from 0-72.  Scores in the 
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range of 0-10 represented nondepressed patients, 11-20 indicated minimal de-
pression, 21-30 indicated mild depression, 31-45 indicated moderate depression, 
and 46+ indicated severe depression.12  Futhermore, a CUDOS score ranging 
from 0-20 represented patients in remission, and scores above 20 represented 
patients who still had depression.12 
By combining the SHAPS and CUDOS into one survey, but still scoring 
separately, we related antidepressant efficacy in terms of depression severity and 
the ability to feel pleasure.   The IBM SPSS statistics (version 23) software was uti-
lized for descriptive statistical analysis. 
 
Results 
Between January 27, 2016 and March 8, 2016, 104 surveys were collected 
with 33 being excluded.  The mean (SD) patient age was 44 (14) years and 83% 
were female (p<0.001).  There were six psychiatric conditions identified in the pa-
tient sample.  All patients had depression, and 66% of patients had a comorbid 
anxiety disorder.  The most common anxiety disorder was general anxiety disor-
der, with over half of all patients presenting with it (Figure 1).   
Ninety percent of patients in the cohort had been on antidepressants for 
over two months; overall, 30% of patients reached remission and 43% of patients 
had anhedonia.  Prevalence of anhedonia was moderately correlated with in-
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creasing depression severity, according to a Spearman’s rho equal to -0.57 
(p<0.001) (Figure 2).  The proportion of patients in the minimal/moderate de-
pression and minimal/severe depression categories were statistically different 
within both the anhedonia and non-anhedonia groups (p<0.001), and no other 
significant differences were observed between depression severity groups for an-
hedonia.  The proportion of patients with anhedonia was 5% in the remission 
group and 59% in the depression group (p<0.001).  There was no statistical dif-
ference in anhedonia prevalence between patients with comorbid anxiety disor-
ders and depression alone. 
About 60% of patients were involved in psychotherapy along with their 
antidepressant regiment, and these patients had a statistically higher prevalence 
of anhedonia compared to patients on antidepressants alone (p=0.018) (Table 1).  
Moreover, 55% of patients participating in psychotherapy were moderately or se-
verely depressed, while 33.3% of patients taking only antidepressants were mod-
erately or severely depressed. 
We compared the scores of individual questions on the CUDOS for pa-
tients with and without anhedonia.  There was a statistically significant difference 
in responses to every question except questions 17, 18, 19, and 21 (Table 2). 
Six common antidepressant classes were found in the cohort:  SSRIs, sero-
tonin-norepinephrine reuptake inhibitors (SNRIs), SSRIs plus bupropion, SNRIs 
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plus bupropion, SSRIs plus antipsychotics, and SNRIs plus antipsychotics.  SSRIs 
and SNRIs were the most common classes of antidepressants prescribed in the 
cohort, and patients in these classes had the lowest prevalence of anhedonia and 
the highest levels of remission (Table 3).  We found a higher prevalence of pa-
tients with moderate depression in the combination drug group (Figure 3), how-
ever, no statistically significant differences were observed for either depression 
severity (p=0.46) or anhedonia (p=0.87) between drug classes. 
 
Discussion 
Tool Selection 
Historically, the best-known scales used to measure the ability to feel 
pleasure have been the Physical Anhedonia Scale (PAS) and the Fawcett-Clark 
Pleasure Scale (FCPS).8  However, these scales are impractical due to their length 
and cultural bias.11  Developed in 1995, the SHAPS provides a simple 14-question 
self-assessment scale that is largely unaffected by social factors and is easy to 
score.11  When compared to the other two pleasure scales, hedonic capacity was 
strongly defined by the SHAPS13, and the tool was proven to be reliable and valid 
while accurately measuring anhedonia without distortion due to age or sex.8 
A common interviewer-administered scale used to assess the severity of 
depression in clinical settings is the Hamilton Depression Ratings Scale (HAM-D).  
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However, the full HAM-D would require too great a time commitment by the 
physicians to be relevant in this study.  The Clinically Useful Depression Outcome 
Scale (CUDOS) is a self-report depression scale that measures depression severity 
in a similar manner to the HAM-D, while taking less time to complete.  A study 
comparing the two scales showed that a valid cutoff for remission (based on the 
HAM-D threshold) was found14, and a CUDOS score could be used to determine 
the severity of depression symptoms.12   
 
Analysis 
The original hypothesis of this study was that anhedonia may be inde-
pendent of depression severity, and may even persist in patients who reach re-
mission.  However, there was a moderate correlation showing that anhedonia 
prevalence actually increased as the depression severity increased.  Furthermore, 
all patients in the severe depression group had anhedonia while none of the pa-
tients in the non-depressed group had anhedonia, and prevalence of anhedoinia 
was substantially lower in the remission group compared to the depression 
group (Fig. 2).  These results lead us to believe that anhedonia is not as persistent 
as previously expected and does relate to depression severity.  We will need to 
see if similar trends occur when we have a larger sample size. 
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The overall efficacy of antidepressants in facilitating remission was poor at 
30%, and anhedonia prevalence was high at 43%.  This is troubling because 90% 
of patients in the study had been taking antidepressants for over two months, 
which is an important threshold where physicians hope to see a significant re-
sponse to treatment.  Yet, the results of our cohort were minimal.  Our findings in 
this area do compare with previous studies4,6, highlighting the poor effectiveness 
of antidepressants overall and specific to anhedonia. 
The objective of this study was not to analyze the effect of psychotherapy 
on anhedonia prevalence, but it became relevant because 60% of patients partic-
ipated in therapy along with their antidepressant regiment.  Patients who were 
involved in psychotherapy tended to have more severe depression and fittingly 
had a statistically higher prevalence of anhedonia (tab. 1).  It is possible that pa-
tients who are more severely depressed had a poor response to their medication 
and needed to supplement their treatment plan with psychotherapy.  We could 
learn more about patient response to psychotherapy by measuring type and du-
ration in the future. 
Patients with anhedonia answered 14 out of 18 questions on the CUDOS 
statistically differently than patients without anhedonia.  This along with the 
moderate correlation between anhedonia prevalence and CUDOS score shows 
that the CUDOS could be utilized to determine presence of anhedonia.  Topics 
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where patients with anhedonia answered similarly to patients without anhedonia 
include changes in appetite, difficulty sleeping, and feeling fidgety (tab. 2), so 
these aspects of depression may be unaffected by anhedonia. 
We cannot confidently claim that SSRIs and SNRIs are the most efficacious 
in alleviating anhedonia due to the cross sectional nature of our survey and low 
sample size.  It is possible that patients on only an SSRI or SNRI had successful 
response to the initial antidepressant treatment and did not need further medica-
tion.  Similarly, patients in the combination medication groups may not have had 
successful response to the initial drug (which was likely an SSRI or SNRI), and 
needed additional pharmacotherapy.  This would explain the high prevalence of 
anhedonia and the low levels of remission in the combination medication groups 
(tab. 3). 
We were unable to look at response to treatment because we did not have 
specific patient medication information.  Performing a longitudinal study in the 
future may be valuable to better observe how depression severity and anhedoina 
change in individual patients over the entire antidepressant treatment period.   
While the drug groups cannot be compared at this point, we can observe 
that for every drug class, most of the distribution was centralized at minimal, 
mild, and moderate depression levels with very few patients at the extremes (Fig. 
3).  One possibility is that all the drug classes may be effective at helping patients 
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decrease the severity of their depression, but are not capable of completely alle-
viating it in most cases. 
In order to more closely examine the effect of different drug classes on the 
prevalence of anhedonia, it will be necessary to perform a longitudinal study and 
have access to patient charts.  Being able to follow individual patients over time 
and knowing the exact duration of their medications would allow for a more sig-
nificant understanding of how various drug classes are affecting anhedonia and 
depression severity over time.  It would also be beneficial to implement a control 
group that has not begun antidepressant treatment, but this would be difficult to 
implement in practice due to ethical considerations. 
We have to be wary in assuming our data is generalizable because of the 
setting and low sample size in some groups.  Since every patient in this study was 
visiting a psychiatrist, it is likely that a primary care physician was unable to ade-
quately address the issue and the initial treatment was not effective.  Therefore, 
patients in this study may have had more severe depression diagnoses than the 
general population.  Moreover, the vast majority of participants were female, 
making it difficult to assume males would have similar responses.  But females 
are twice as likely to be diagnosed with depression as compared to males15, so 
our patient sample was not too significantly skewed from depression rates in the 
general population. 
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Conclusion 
It appears that focusing on the treatment of a patient’s depression as a 
whole is the most effective strategy to treat anhedonia.  We did not find a specif-
ic antidepressant class or any other factor that had a significant advantage in 
treating anhedonia compared to others.  Performing a longitudinal study with 
access to patient medication charts would be the next step to validate the find-
ings of this study. 
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Appendix:  Paper Survey 
 
 
Check the following conditions you are currently being treated for… 
 
⃝  Depression 
⃝  General Anxiety Disorder (GAD) 
⃝  Post Traumatic Stress Disorder (PTSD) 
⃝  Obsessive Compulsive Disorder (OCD) 
⃝  Attention-Deficit/Hyperactivity Disorder (ADHD) 
⃝  Social Anxiety Disorder (SAD) 
⃝  Schizophrenia  
⃝  Bipolar Disorder 
⃝  Substance Abuse Disorder  
 
 
IF YOU CHECKED SCHIZOPHRENIA, BIPOLAR DISORDER, OR SUBSTANCE ABUSE DISORDER YOU ARE 
FINISHED WITH THIS SURVEY.  IF YOU CHECKED DEPRESSION PLEASE COMPLETE THE FOLLOWING QUES-
TIONS. 
 
 
 
When did you begin taking antidepressants for your current episode of depression? 
 
a) Within the last 2 months 
 
b) More than 2 months ago 
 
Are you currently participating in any type of psychotherapy? 
a) Yes 
 
b) No  
 
 
 
What is your age? 
 
 
 
What is your sex? 
 
 
What antidepressant medication(s) do you take for your current episode of depression? 
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This questionnaire is designed to measure your ability to experience pleasure in the last few days.   
It is important to read each statement very carefully.  
Tick one of the boxes to indicate how much you agree or disagree with each statement. 
  
  
 
 Strongly 
disagree Disagree Agree 
Strongly 
agree 
1. I would enjoy my favorite television or radio 
program. 
 
    
2. I would enjoy being with my family or close 
friends. 
 
    
3. I would find pleasure in my hobbies and pas-
times. 
 
    
4. I would be able to enjoy my favorite meal. 
 
    
5. I would enjoy a warm bath or refreshing shower. 
 
    
6. I would find pleasure in the scent of flowers or 
the smell of a fresh sea breeze or freshly baked 
bread. 
 
    
7. I would enjoy seeing other people’s smiling fac-
es. 
 
    
8. I would enjoy looking smart when I have made 
an effort with my appearance. 
 
    
9. I would enjoy reading a book, magazine, or 
newspaper. 
 
    
10. I would enjoy a cup of tea or coffee or my fa-
vorite drink. 
 
    
11. I would find pleasure in small things, e.g. bright 
sunny day, a telephone call from my friend. 
 
    
12. I would be able to enjoy a beautiful landscape 
or view. 
 
    
13. I would get pleasure from helping others. 
 
    
14. I would feel pleasure when I receive praise from 
other people. 
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For each item, please indicate how well the statement describes you during the past week, including to-
day.  Circle the number in the columns next to the item that best describes you. 
0 = not at all true (zero days) 
1 = rarely true (1-2 days) 
2 = sometimes true (3-4 days) 
3 = often true (5-6 days) 
4 = almost always true (every day) 
      
 0 1 2 3 4 
15. I felt sad or depressed. 
 
     
16. I was not as interested in my usual activities. 
 
     
17. My appetite was poor, and I didn’t feel like eating. 
 
     
18. My appetite was much greater than usual. 
 
     
19. I had difficulty sleeping. 
 
     
20. I was sleeping too much. 
 
     
21. I felt very fidgety, making it difficult to sit still 
 
     
22. I felt physically slowed down, like my body was stuck in 
mud. 
 
     
23. My energy level was low. 
 
     
24. I felt guilty. 
 
     
25. I thought I was a failure. 
 
     
26. I had problems concentrating. 
 
     
27. I had more difficulties making decisions than usual. 
 
     
28. I wished I was dead. 
 
     
29. I thought about killing myself. 
 
     
30. I thought that the future looked hopeless. 
 
     
 
31. Overall, how much have the symptoms of 
depression interfered with or caused diffi-
culties in your life during the past week? 
 
0) Not at all 
1) A little bit 
2) A moderate amount 
3) Quite a bit 
4) Extremely 
 
32. How would you rate your overall quality of 
life during the past week? 
 
0) Very good; my life could hardly be better 
1) Pretty good; most things are going well 
2) The good and the bad parts are about 
equal 
3) Pretty bad; most things are going poorly 
4) Very bad; my life could hardly be worse 
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Tables and Figures 
 
 
Figure 1.  Frequency of mental illnesses present in cohort (N=71) 
 
*data reported as n (%) 
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Figure 2.  Frequency of patients and prevalence of anhedonia in each depression 
severity category (N=70). 
 
*Patients with anhedonia is reported category (%) 
**Frequency is reported n (%) 
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Table 1:  Frequency of anhedonia and remission in patients treated with antide-
pressant(s) and in patients treated with antidepressant(s) plus psychotherapy. 
 
Frequency 
(N=67) 
Anhedonia 
(N=66) 
Remission 
(N=67) 
    
Antidepressant therapy 40% 23% 37% 
    
Antidepressant plus psycho-
therapy 
 
60% 53% 30% 
*data reported n (%) 
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Table 2:  Scoring of CUDOS questions for patients with anhedonia and without 
anhedonia. 
Question Topic p value 
15 I felt sad or depressed < 0.001* 
16 I was not as interested in my usual activities 0.001* 
17 My appetite was poor, and I didn't feel like eating 0.058** 
18 My appetite was much greater than usual 0.671** 
19 I had difficulty sleeping 0.855** 
20 I was sleeping too much <0.001* 
21 I felt very fidgety, making it difficult to sit still 0.061** 
22 I felt physically slowed down, like my body was stuck in mud <0.001* 
23 My energy level was low 0.001* 
24 I felt guilty 0.012* 
25 I thought I was a failure <0.001* 
26 I had problems concentrating 0.025* 
27 I had more difficulties making decisions than usual 0.006* 
28 I wished I was dead <0.001* 
29 I thought about killing myself 0.008* 
30 I thought the future looked hopeless <0.001* 
31 Overall, how much have the symptoms of depression interfered or 
caused difficulties in your life during the past week 
0.002* 
32 How would you rate your overall quality of life during the past week <0.001* 
*P value (bold) represents statistically different reponses 
**P value (italized) represents statistically not different responses  
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Table 3:  Frequency of anhedonia and remission in patients being treated with 
various antidepressant classes. 
 
Frequency 
(N=67) 
Anhedonia 
(N=66) 
Remission 
(N=67) 
    
SSRI 21% 31% 57% 
SNRI 18% 25% 42% 
SSRI + bupropion 9% 50% 33% 
SNRI + bupropion 9% 50% 33% 
SSRI + antipsychotic 8% 40% 20% 
SNRI + antipsychotic 6% 50% 25% 
Other 30% 45% 15% 
    
*data reported n (%) 
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Figure 3.  Distribution of depression severity for drugs classes (N=67) 
 
*data reported as category (%) 
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